Literature DB >> 10933704

Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

X Da Costa1, M F Kramer, J Zhu, M A Brockman, D M Knipe.   

Abstract

A number of studies have shown that replication-defective mutant strains of herpes simplex virus (HSV) can induce protective immunity in animal systems against wild-type HSV challenge. However, all of those studies used viruses with single mutations. Because multiple, stable mutations provide optimal levels of safety for live vaccines, we felt that additional mutations needed to be engineered into a candidate vaccine strain for HSV-2 and genital herpes. We therefore isolated an HSV-2 strain with deletion mutations in two viral DNA replication protein genes, UL5 and UL29. The resulting double deletion mutant virus strain, dl5-29, fails to form plaques or to give any detectable single cycle yields in normal monkey or human cells. Nevertheless, dl5-29 expresses nearly the same pattern of gene products as the wild-type virus or the single mutant viruses and induces antibody titers in mice that are equivalent to those induced by single deletion mutant viruses. Therefore, it is feasible to isolate a mutant HSV strain with two mutations in essential genes and with an increased level of safety but which is still highly immunogenic.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933704      PMCID: PMC112327          DOI: 10.1128/jvi.74.17.7963-7971.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein.

Authors:  M Gao; D M Knipe
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

2.  Prior herpes simplex virus type 2 infection as a risk factor for HIV infection.

Authors:  S D Holmberg; J A Stewart; A R Gerber; R H Byers; F K Lee; P M O'Malley; A J Nahmias
Journal:  JAMA       Date:  1988-02-19       Impact factor: 56.272

3.  The UL5 gene of herpes simplex virus type 1: isolation of a lacZ insertion mutant and association of the UL5 gene product with other members of the helicase-primase complex.

Authors:  L A Zhu; S K Weller
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration.

Authors:  S L Highlander; W H Cai; S Person; M Levine; J C Glorioso
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

5.  Genetic identification of a portion of the herpes simplex virus ICP8 protein required for DNA-binding.

Authors:  M Gao; J Bouchey; K Curtin; D M Knipe
Journal:  Virology       Date:  1988-04       Impact factor: 3.616

6.  Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection.

Authors:  L H Nguyen; D M Knipe; R W Finberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted.

Authors:  A Forrester; H Farrell; G Wilkinson; J Kaye; N Davis-Poynter; T Minson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

8.  Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals.

Authors:  E W Hook; R O Cannon; A J Nahmias; F F Lee; C H Campbell; D Glasser; T C Quinn
Journal:  J Infect Dis       Date:  1992-02       Impact factor: 5.226

9.  Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.

Authors:  L A Morrison; D M Knipe
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

Review 10.  The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1.

Authors:  D J McGeoch; M A Dalrymple; A J Davison; A Dolan; M C Frame; D McNab; L J Perry; J E Scott; P Taylor
Journal:  J Gen Virol       Date:  1988-07       Impact factor: 3.891

View more
  53 in total

1.  Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.

Authors:  Christopher S Morello; Michael S Levinson; Kimberly A Kraynyak; Deborah H Spector
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

3.  Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells.

Authors:  Ayuko Sato; Melissa M Linehan; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-03       Impact factor: 11.205

4.  Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa.

Authors:  Timothy E Dudek; Ernesto Torres-Lopez; Clyde Crumpacker; David M Knipe
Journal:  J Infect Dis       Date:  2011-04-14       Impact factor: 5.226

5.  Herpesviral replication compartments move and coalesce at nuclear speckles to enhance export of viral late mRNA.

Authors:  Lynne Chang; William J Godinez; Il-Han Kim; Marco Tektonidis; Primal de Lanerolle; Roland Eils; Karl Rohr; David M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

6.  A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.

Authors:  Lesia K Dropulic; Makinna C Oestreich; Harlan L Pietz; Kerry J Laing; Sally Hunsberger; Keith Lumbard; Doreen Garabedian; Siu Ping Turk; Aiying Chen; Ronald L Hornung; Chetan Seshadri; Malisa T Smith; Nancy A Hosken; Sanjay Phogat; Lee-Jah Chang; David M Koelle; Kening Wang; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2019-08-09       Impact factor: 5.226

Review 7.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

8.  A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.

Authors:  Elizabeth E Brittle; Fushan Wang; John M Lubinski; Ralph M Bunte; Harvey M Friedman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

9.  Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.

Authors:  Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Juan Lacayo; Timothy Dudek; David M Knipe; Stephen E Straus; Jeffrey I Cohen
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

Review 10.  Rationalizing the development of live attenuated virus vaccines.

Authors:  Adam S Lauring; Jeremy O Jones; Raul Andino
Journal:  Nat Biotechnol       Date:  2010-06-07       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.